After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
MultiPlan: Chancery court assesses fiduciary duties in the context of de-SPAC transactions -
The Delaware Court of Chancery declined to dismiss, at the pleading stage, breach of fiduciary duty claims made against a SPAC's...more
9/13/2022
/ Acquisitions ,
Board of Directors ,
Breach of Duty ,
Class Action ,
Controlling Stockholders ,
Corporate Counsel ,
DE Supreme Court ,
Delaware ,
Fiduciary Duty ,
Financial Adviser ,
Healthcare ,
Shareholders ,
Special Purpose Acquisition Companies (SPACs)
Dealmaking activity in the US healthcare sector was robust in H1 2022 in the face of various macroeconomic headwinds. There were US$92.4 billion worth of deals announced in H1 2022. This was a 51 percent decrease from a...more
Technology M&A activity is thriving in 2021 as dealmakers continue to turn to the sector in search of assets with high-quality earnings and growth prospects -
Technology deal volume and value surged through the first half...more
7/30/2021
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Digital Health ,
Domestic Dealmaking ,
Global Dealmaking ,
Healthcare ,
Mergers ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs) ,
Technology Sector